DIA today announced the next in its Solution Provider educational webinar series – this one being held in cooperation with Cytel. On October 22, DIA will host: Planning and Implementing Large Cardiovascular Outcomes Studies: Opportunities & Challenges.
Cytel is collaborating with DIA to participate in its newly-created Solution Provider Webinar Program.
DIA’s educational collaboration with Cytel brings together leading scientists and thought leaders from industry who will host this webinar.
Register today for the no-charge October 22 webinar to learn from experts:
Paul Strumph, MD, Lexicon Pharmaceuticals', Vice President, Clinical Development
, Cytel Senior Director, Adaptive Implementation, Strategic Consulting
All Solution Provider webinars are free to DIA customers and will feature topics including oncology, strategies for late phase development, biomarkers and technology as an enabler of clinical development services.
Susan Cantrell, Director, North America at DIA said, “We are excited to host what will prove to be an insightful and in depth discussion. Today, international regulators are calling sponsors to increasingly conduct CV outcomes studies. The costs necessitated by the additional research will be measured in the $100’s of millions of dollars per program. The full impact to be felt by every sponsor, of any size engaged in therapeutic areas where cardio-related events are a concern.”
Cytel’s Senior Director of Adaptive Implementation, Zoran Antonijevic said, “We are pleased to work with the DIA to share the recent experiences with managing larger CV Outcomes trials. Our goal is to help sponsor organization begin to formulate responses to critical questions -- How to best assess necessity, choose the design strategy, and determine timing? Which development path is optimal: add-on studies or a more parallel approach? Do we choose a non–inferiority approach for approval? A non-inferiority trial in a post-marketing setting?”
ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at www.diahome.org and follow DIA at: LinkedIn, Twitter, YouTube, Facebook, Flickr and Pinterest.
Eric Rosen | +1.215.290.9153 | Eric.Rosen@diahome.org
ABOUT CYTEL: The clinical development of drugs and devices is a crucial contribution to human welfare. We stand committed to improving the success rates of the clinical development process through the application of statistical science and innovative technology.
All 25 leading global pharmaceutical, biotech and medical device companies rely on Cytel when planning and implementing their clinical studies. Pioneers in adaptive trials, every adaptive design submitted for regulatory review has been deemed acceptable.